Acute Exacerbations in Idiopathic Pulmonary Fibrosis
- Seamus P. Crowley, MD;
- Peter Kelly, MD, MS; and
- Jim J. Egan, MD
- From Mater Misericordiae Hospital, Dublin 7, Ireland.
TO THE EDITOR:
The data provided by Martinez and colleagues (1) are a further example of the merits of offering treatment to patients with idiopathic pulmonary fibrosis (IPF) only as part of a therapeutic trial. Although the large international study of interferon-γ use in IPF was mostly negative, the data gleaned from the placebo group are critical to our understanding of …
This 100-word excerpt has been provided in the absence of an abstract.
Most Read
